Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 152


Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.

Novelli EM, Kato GJ, Ragni MV, Zhang Y, Hildesheim ME, Nouraie M, Barge S, Meyer MP, Hassett AC, Gordeuk VR, Gladwin MT, Isenberg JS.

Am J Hematol. 2012 Mar;87(3):326-30. doi: 10.1002/ajh.22274. Epub 2012 Feb 8.


Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.


Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.

Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.

JAMA. 2003 Apr 2;289(13):1645-51. Erratum in: JAMA. 2003 Aug 13;290(6):756.


Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.


[How I treat ... sickle cell anemia: current therapies].

Rezaei Kalantari H.

Rev Med Liege. 2001 Oct;56(10):671-5. Review. French.


Severity of Brazilian sickle cell disease patients: severity scores and feasibility of the Bayesian network model use.

Belini Junior E, Silva DG, Torres Lde S, Okumura JV, Lobo CL, Bonini-Domingos CR.

Blood Cells Mol Dis. 2015 Apr;54(4):321-7. doi: 10.1016/j.bcmd.2015.01.011. Epub 2015 Feb 23.


Sickle cell disease clinical phenotypes in children from South-Western, Nigeria.

Adegoke SA, Adeodu OO, Adekile AD.

Niger J Clin Pract. 2015 Jan-Feb;18(1):95-101. doi: 10.4103/1119-3077.146987.


Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.

Elbarbary NS, Ismail EA, Roushdy A, Fahmy E.

Blood Cells Mol Dis. 2016 Mar;57:1-7. doi: 10.1016/j.bcmd.2015.11.001. Epub 2015 Nov 10.


Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.

Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE; Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH)..

Am J Hematol. 2013 Nov;88(11):932-8. doi: 10.1002/ajh.23547. Epub 2013 Aug 30.


Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Blood Cells Mol Dis. 2000 Oct;26(5):453-66.


Hydroxyurea therapy: improving the lives of patients with sickle cell disease.

Anderson N.

Pediatr Nurs. 2006 Nov-Dec;32(6):541-3. Review.


Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.

Blood. 1997 Apr 1;89(7):2554-9.


Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.

Stallworth JR, Jerrell JM, Tripathi A.

Am J Hematol. 2010 Oct;85(10):795-7. doi: 10.1002/ajh.21772.


Plasma PTX3 levels in sickle cell disease patients, during vaso occlusion and acute chest syndrome (data from Saudi population).

Elshazly SA, Heiba NM, Abdelmageed WM.

Hematology. 2014 Jan;19(1):52-9. doi: 10.1179/1607845413Y.0000000092. Epub 2013 Nov 25.


Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.

Tantawy AA, Adly AA, Ismail EA, Darwish YW, Ali Zedan M.

Blood Cells Mol Dis. 2014 Dec;53(4):189-93. doi: 10.1016/j.bcmd.2014.07.003. Epub 2014 Jul 25.


Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.

Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.

Pediatr Hematol Oncol. 1999 May-Jun;16(3):221-32.


Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW; BABY HUG investigators..

Lancet. 2011 May 14;377(9778):1663-72. doi: 10.1016/S0140-6736(11)60355-3.


Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.

Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.


Relationship of erythropoietin, fetal hemoglobin, and hydroxyurea treatment to tricuspid regurgitation velocity in children with sickle cell disease.

Gordeuk VR, Campbell A, Rana S, Nouraie M, Niu X, Minniti CP, Sable C, Darbari D, Dham N, Onyekwere O, Ammosova T, Nekhai S, Kato GJ, Gladwin MT, Castro OL.

Blood. 2009 Nov 19;114(21):4639-44. doi: 10.1182/blood-2009-04-218040. Epub 2009 Sep 1.


Soluble Fas/FasL ratio as a marker of vasculopathy in children and adolescents with sickle cell disease.

Adly AA, Ismail EA, Andrawes NG, Mahmoud MM, Eladawy R.

Cytokine. 2016 Mar;79:52-8. doi: 10.1016/j.cyto.2015.12.022. Epub 2016 Jan 5.


Supplemental Content

Support Center